Physician profile
John Mathew
NPI 1679778526
$50,268.44
in general payments reported to CMS, 2019-2025
17 companies · $666 in 2025
The $666 reported for 2025 was more than what 94% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $163 · 2021: $304 · 2022: $536 · 2023: $249 · 2024: $538 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,452.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $47,389.57 | 2019 | |
| Pfizer INC. | $546.73 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $524.85 | 2019-2025 | Andexxa |
| Janssen Pharmaceuticals, INC | $359.80 | 2023-2024 | Xarelto |
| Ceribell, INC. | $296.92 | 2025 | Pocket Eeg Device |
| Octapharma USA, INC. | $276.86 | 2025 | Balfaxar |
| Amgen INC. | $145.87 | 2024 | Repatha |
| Abbvie INC. | $144.43 | 2021 | |
| Inari Medical, INC. | $136.14 | 2022 | |
| Organogenesis INC. | $124.42 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.70 | 2019-2024 | Jardiance |
| Smith+Nephew, INC. | $89.91 | 2024 | Pico, Collagenase Santyl, Renasys Go V2 Home |
| Allergan, INC. | $55.10 | 2019 | |
| Melinta Therapeutics, LLC | $24.39 | 2023 | Orbactiv, Kimyrsa, Vabomere |
| Merck Sharp & Dohme LLC | $24.01 | 2024 | Recarbrio, Zerbaxa, Dificid |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $19.44 | 2025 | Terlivaz |
| Lilly USA, LLC | $16.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.